196 related articles for article (PubMed ID: 15229146)
1. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications.
Dobiásová M
Clin Chem; 2004 Jul; 50(7):1113-5. PubMed ID: 15229146
[No Abstract] [Full Text] [Related]
2. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes.
Tan MH; Johns D; Glazer NB
Clin Chem; 2004 Jul; 50(7):1184-8. PubMed ID: 15117857
[TBL] [Abstract][Full Text] [Related]
3. The role of pioglitazone in modifying the atherogenic lipoprotein profile.
Hanefeld M
Diabetes Obes Metab; 2009 Aug; 11(8):742-56. PubMed ID: 19519869
[TBL] [Abstract][Full Text] [Related]
4. Actos (pioglitazone): a new treatment for type 2 diabetes.
Lawrence JM; Reckless JP
Hosp Med; 2001 Jul; 62(7):411-6. PubMed ID: 11480129
[TBL] [Abstract][Full Text] [Related]
5. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
[No Abstract] [Full Text] [Related]
6. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
Winkler K; Konrad T; Füllert S; Friedrich I; Destani R; Baumstark MW; Krebs K; Wieland H; März W
Diabetes Care; 2003 Sep; 26(9):2588-94. PubMed ID: 12941723
[TBL] [Abstract][Full Text] [Related]
7. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
8. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
Nicholls SJ; Tuzcu EM; Wolski K; Bayturan O; Lavoie A; Uno K; Kupfer S; Perez A; Nesto R; Nissen SE
J Am Coll Cardiol; 2011 Jan; 57(2):153-9. PubMed ID: 21211686
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
10. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
Polonsky T; Mazzone T; Davidson M
Trends Cardiovasc Med; 2009 Apr; 19(3):94-9. PubMed ID: 19679266
[TBL] [Abstract][Full Text] [Related]
11. Lowering the triglyceride/high-density lipoprotein cholesterol and its association with the beneficial impact of pioglitazone on coronary atherosclerosis in the PERISCOPE study is likely due to lowering insulin resistance.
Bell DS; O'Keefe JH
J Am Coll Cardiol; 2011 Aug; 58(7):778. PubMed ID: 21816321
[No Abstract] [Full Text] [Related]
12. Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial.
Geohas J; Daly A; Juturu V; Finch M; Komorowski JR
Am J Med Sci; 2007 Mar; 333(3):145-53. PubMed ID: 17496732
[TBL] [Abstract][Full Text] [Related]
13. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
[TBL] [Abstract][Full Text] [Related]
15. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
[TBL] [Abstract][Full Text] [Related]
16. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
17. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
[TBL] [Abstract][Full Text] [Related]
18. PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Erdmann E; Dormandy J; Wilcox R; Massi-Benedetti M; Charbonnel B
Vasc Health Risk Manag; 2007; 3(4):355-70. PubMed ID: 17969365
[TBL] [Abstract][Full Text] [Related]
19. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
20. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients.
Jun JK; Gong WC; Mathur R
Am J Health Syst Pharm; 2003 Mar; 60(5):469-73. PubMed ID: 12635453
[No Abstract] [Full Text] [Related]
[Next] [New Search]